Insider Trading activities at Alder Biopharmaceuticals Inc (ALDR)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alder Biopharmaceuticals Inc (ALDR) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Alder Biopharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1423824.

Total stock buying since 2014: $17,830,000.
Total stock sales since 2014: $105,562,501.
Total stock option exercises since 2014: $1,761,830.

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Alder Biopharmaceuticals Inc* (*ALDR*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2019	85,923,561	$0	39,531	$697,113	32,728	$129,602
2018	0	$0	234,411	$3,910,808	234,411	$791,923
2017	30,000	$300,000	74,638	$1,398,238	101,908	$156,111
2016	0	$0	328,179	$9,738,894	341,179	$386,240
2015	0	$0	2,339,750	$88,880,569	433,288	$297,954
2014	1,753,000	$17,530,000	59,090	$936,879	0	$0

Table 2. Monthly summary of insider trading at *Alder Biopharmaceuticals Inc* (*ALDR*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2019-10	85,923,561	$0	0	$0	0	$0
2019-09	0	$0	32,728	$603,504	32,728	$129,602
2019-04	0	$0	6,803	$93,609	0	$0
2018-12	0	$0	5,044	$69,824	5,044	$4,993
2018-11	0	$0	30,042	$407,388	30,042	$214,580
2018-10	0	$0	30,039	$469,008	30,039	$132,858
2018-09	0	$0	30,039	$540,381	30,039	$91,610
2018-08	0	$0	30,039	$587,695	30,039	$91,610
2018-07	0	$0	37,160	$575,370	37,160	$102,673
2018-06	0	$0	59,887	$1,078,387	59,887	$137,547
2018-05	0	$0	12,161	$182,755	12,161	$16,052
2017-11	0	$0	16,519	$178,487	43,789	$62,761
2017-10	0	$0	16,520	$203,708	16,520	$27,258
2017-07	30,000	$300,000	0	$0	0	$0
2017-06	0	$0	585	$11,700	585	$579
2017-02	0	$0	30,000	$750,750	30,000	$49,500
2017-01	0	$0	11,014	$253,593	11,014	$16,013
2016-12	0	$0	19,908	$460,326	19,908	$32,847
2016-11	0	$0	23,000	$627,157	23,000	$37,950
2016-10	0	$0	27,181	$827,076	21,181	$31,798
2016-09	0	$0	23,000	$748,131	23,000	$34,099
2016-08	0	$0	23,000	$727,493	23,000	$34,099
2016-07	0	$0	20,000	$582,226	45,000	$38,773
2016-06	0	$0	42,090	$1,271,288	36,090	$49,502

Table 3. Detailed insider trading at *Alder Biopharmaceuticals Inc* (*ALDR*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2019-10-22	H Lundbeck A S (10% Owner)	Buy	85,923,561	.00	0
2019-09-16	Smith Jeffrey T L (Managing Director)	Sale	32,728	18.44	603,504
2019-09-16	Smith Jeffrey T L (Managing Director)	Option Ex	32,728	3.96	129,602
2019-04-25	Lavelle Erin (Chief Operating Officer)	Sale	1,434	13.67	19,599
2019-04-25	Bucher James B (EVP & General Counsel)	Sale	1,897	13.85	26,281
2019-04-25	Hassler Randal (EVP, Pharmaceutical Ops.)	Sale	1,738	13.85	24,067
2019-04-25	Benedict Larry (EVP and PAO)	Sale	1,734	13.65	23,662
2018-12-03	Smith Jeffrey T L (Managing Director)	Sale	5,044	13.84	69,824
2018-12-03	Smith Jeffrey T L (Managing Director)	Option Ex	5,044	.99	4,993
2018-11-01	Latham John A (Chief Scientific Officer)	Sale	25,002	13.59	339,752
2018-11-01	Latham John A (Chief Scientific Officer)	Option Ex	25,002	8.38	209,591
2018-11-01	Smith Jeffrey T L (Managing Director)	Sale	5,040	13.42	67,636
2018-11-01	Smith Jeffrey T L (Managing Director)	Option Ex	5,040	.99	4,989
2018-10-01	Latham John A (Chief Scientific Officer)	Sale	24,999	15.61	390,309
2018-10-01	Latham John A (Chief Scientific Officer)	Option Ex	24,999	5.12	127,869
2018-10-01	Smith Jeffrey T L (Managing Director)	Sale	5,040	15.62	78,699
2018-10-01	Smith Jeffrey T L (Managing Director)	Option Ex	5,040	.99	4,989
2018-09-04	Latham John A (Chief Scientific Officer)	Sale	24,999	17.99	449,682
2018-09-04	Latham John A (Chief Scientific Officer)	Option Ex	24,999	3.46	86,621
2018-09-04	Smith Jeffrey T L (Managing Director)	Sale	5,040	18.00	90,699
2018-09-04	Smith Jeffrey T L (Managing Director)	Option Ex	5,040	.99	4,989
2018-08-01	Latham John A (Chief Scientific Officer)	Sale	24,999	19.55	488,780
2018-08-01	Latham John A (Chief Scientific Officer)	Option Ex	24,999	3.46	86,621
2018-08-01	Smith Jeffrey T L (Managing Director)	Sale	5,040	19.63	98,915
2018-08-01	Smith Jeffrey T L (Managing Director)	Option Ex	5,040	.99	4,989
2018-07-02	Latham John A (Chief Scientific Officer)	Sale	24,999	15.48	387,009
2018-07-02	Latham John A (Chief Scientific Officer)	Option Ex	24,999	3.46	86,621
2018-07-02	Smith Jeffrey T L (Managing Director)	Sale	12,161	15.49	188,361
2018-07-02	Smith Jeffrey T L (Managing Director)	Option Ex	12,161	1.32	16,052
2018-06-01	Latham John A (Chief Scientific Officer)	Sale	24,999	18.00	450,081
2018-06-01	Latham John A (Chief Scientific Officer)	Option Ex	24,999	3.96	98,996
2018-06-01	Litton Mark James (Chief Business Officer)	Sale	22,727	17.99	408,813
2018-06-01	Litton Mark James (Chief Business Officer)	Option Ex	22,727	.99	22,499
2018-06-01	Smith Jeffrey T L (Managing Director)	Sale	12,161	18.05	219,493
2018-06-01	Smith Jeffrey T L (Managing Director)	Option Ex	12,161	1.32	16,052
2018-05-16	Smith Jeffrey T L (Managing Director)	Sale	12,161	15.03	182,755
2018-05-16	Smith Jeffrey T L (Managing Director)	Option Ex	12,161	1.32	16,052
2017-11-13	Litton Mark James (Chief Business Officer)	Sale	16,519	10.80	178,487
2017-11-13	Litton Mark James (Chief Business Officer)	Option Ex	16,519	1.65	27,256
2017-11-01	Siegall Clay B (Director)	Option Ex	27,270	1.30	35,505
2017-10-16	Litton Mark James (Chief Business Officer)	Sale	16,520	12.33	203,708
2017-10-16	Litton Mark James (Chief Business Officer)	Option Ex	16,520	1.65	27,258
2017-07-18	Yarno Wendy L (Director)	Buy	5,000	10.00	50,000
2017-07-18	Dow Stephen M (Director)	Buy	25,000	10.00	250,000
2017-06-20	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	585	20.00	11,700
2017-06-20	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	585	.99	579
2017-02-09	Schatzman Randall C (President and CEO)	Sale	30,000	25.02	750,750
2017-02-09	Schatzman Randall C (President and CEO)	Option Ex	30,000	1.65	49,500
2017-01-18	Litton Mark James (Chief Business Officer)	Sale	1,498	23.10	34,599
2017-01-18	Litton Mark James (Chief Business Officer)	Option Ex	1,498	1.65	2,471
2017-01-09	Litton Mark James (Chief Business Officer)	Sale	500	23.00	11,500
2017-01-09	Litton Mark James (Chief Business Officer)	Option Ex	500	1.65	825
2017-01-06	Litton Mark James (Chief Business Officer)	Sale	6,800	23.02	156,522
2017-01-06	Litton Mark James (Chief Business Officer)	Option Ex	6,800	1.46	9,914
2017-01-05	Litton Mark James (Chief Business Officer)	Sale	2,216	23.00	50,972
2017-01-05	Litton Mark James (Chief Business Officer)	Option Ex	2,216	1.26	2,803
2016-12-01	Latham John A (Chief Scientific Officer)	Sale	7,272	23.13	168,200
2016-12-01	Latham John A (Chief Scientific Officer)	Option Ex	7,272	1.65	11,998
2016-12-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	6,000	23.11	138,684
2016-12-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	6,000	1.65	9,900
2016-11-09	Latham John A (Chief Scientific Officer)	Sale	10,000	30.18	301,840
2016-11-09	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.65	16,500
2016-11-07	Schatzman Randall C (President and CEO)	Sale	10,000	25.16	251,610
2016-11-07	Schatzman Randall C (President and CEO)	Option Ex	10,000	1.65	16,500
2016-11-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,000	24.57	73,707
2016-11-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,000	1.65	4,950
2016-10-17	Litton Mark James (Chief Business Officer)	Sale	6,000	27.50	165,000
2016-10-03	Latham John A (Chief Scientific Officer)	Sale	10,000	31.25	312,510
2016-10-03	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.65	16,500
2016-10-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,000	31.31	93,918
2016-10-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,000	1.65	4,950
2016-10-03	Schatzman Randall C (President and CEO)	Sale	8,181	31.25	255,648
2016-10-03	Schatzman Randall C (President and CEO)	Option Ex	8,181	1.26	10,348
2016-09-01	Latham John A (Chief Scientific Officer)	Sale	10,000	32.49	324,950
2016-09-01	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.65	16,500
2016-09-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,000	32.79	98,361
2016-09-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,000	1.65	4,950
2016-09-01	Schatzman Randall C (President and CEO)	Sale	10,000	32.48	324,820
2016-09-01	Schatzman Randall C (President and CEO)	Option Ex	10,000	1.26	12,649
2016-08-15	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,000	31.17	93,513
2016-08-15	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,000	1.65	4,950
2016-08-01	Latham John A (Chief Scientific Officer)	Sale	10,000	31.72	317,230
2016-08-01	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.65	16,500
2016-08-01	Schatzman Randall C (President and CEO)	Sale	10,000	31.68	316,750
2016-08-01	Schatzman Randall C (President and CEO)	Option Ex	10,000	1.26	12,649
2016-07-27	Latham John A (Chief Scientific Officer)	Sale	9,187	30.15	277,024
2016-07-27	Latham John A (Chief Scientific Officer)	Option Ex	9,187	1.65	15,158
2016-07-26	Latham John A (Chief Scientific Officer)	Sale	813	30.00	24,392
2016-07-26	Latham John A (Chief Scientific Officer)	Option Ex	813	1.65	1,341
2016-07-25	Schatzman Randall C (President and CEO)	Sale	10,000	28.08	280,810
2016-07-25	Schatzman Randall C (President and CEO)	Option Ex	10,000	1.26	12,649
2016-07-12	Litton Mark James (Chief Business Officer)	Option Ex	25,000	.39	9,625
2016-06-13	Litton Mark James (Chief Business Officer)	Sale	6,000	29.25	175,524
2016-06-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	16,090	30.87	496,714
2016-06-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	16,090	1.26	20,353
2016-06-01	Latham John A (Chief Scientific Officer)	Sale	10,000	30.02	300,220
2016-06-01	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.65	16,500
2016-06-01	Schatzman Randall C (President and CEO)	Sale	10,000	29.88	298,830
2016-06-01	Schatzman Randall C (President and CEO)	Option Ex	10,000	1.26	12,649
2016-05-31	Latham John A (Chief Scientific Officer)	Sale	33,599	30.04	1,009,280
2016-05-31	Latham John A (Chief Scientific Officer)	Option Ex	33,599	1.46	48,987
2016-05-31	Litton Mark James (Chief Business Officer)	Sale	19,720	30.05	592,566
2016-05-31	Litton Mark James (Chief Business Officer)	Option Ex	19,720	.39	7,592
2016-05-27	Latham John A (Chief Scientific Officer)	Sale	6,401	30.05	192,337
2016-05-27	Latham John A (Chief Scientific Officer)	Option Ex	6,401	1.26	8,097
2016-05-27	Litton Mark James (Chief Business Officer)	Sale	5,280	30.06	158,695
2016-05-27	Litton Mark James (Chief Business Officer)	Option Ex	5,280	.39	2,032
2016-05-24	Schatzman Randall C (President and CEO)	Sale	4,017	28.03	112,588
2016-05-24	Schatzman Randall C (President and CEO)	Option Ex	4,017	1.26	5,081
2016-05-23	Schatzman Randall C (President and CEO)	Sale	2,997	28.01	83,951
2016-05-23	Schatzman Randall C (President and CEO)	Option Ex	2,997	1.26	3,791
2016-05-20	Schatzman Randall C (President and CEO)	Sale	2,986	28.01	83,634
2016-05-20	Schatzman Randall C (President and CEO)	Option Ex	2,986	1.26	3,777
2016-04-18	Schatzman Randall C (President and CEO)	Sale	4,514	28.08	126,744
2016-04-18	Schatzman Randall C (President and CEO)	Option Ex	4,514	1.26	5,710
2016-04-15	Schatzman Randall C (President and CEO)	Sale	14,024	28.11	394,144
2016-04-15	Schatzman Randall C (President and CEO)	Option Ex	14,024	.82	11,569
2016-04-14	Schatzman Randall C (President and CEO)	Sale	11,462	28.01	321,073
2016-04-14	Schatzman Randall C (President and CEO)	Option Ex	11,462	.39	4,412
2016-01-04	Latham John A (Chief Scientific Officer)	Sale	10,000	31.55	315,520
2016-01-04	Latham John A (Chief Scientific Officer)	Option Ex	10,000	1.26	12,649
2016-01-04	Litton Mark James (Chief Business Officer)	Sale	25,000	31.52	788,125
2016-01-04	Litton Mark James (Chief Business Officer)	Option Ex	25,000	.39	9,625
2016-01-04	Schatzman Randall C (President and CEO)	Sale	10,000	31.65	316,540
2016-01-04	Schatzman Randall C (President and CEO)	Option Ex	10,000	.39	3,850
2015-12-01	Latham John A (Chief Scientific Officer)	Sale	4,550	37.24	169,451
2015-12-01	Latham John A (Chief Scientific Officer)	Option Ex	4,550	.39	1,751
2015-12-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	4,272	37.24	159,102
2015-12-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	4,272	.39	1,644
2015-12-01	Schatzman Randall C (President and CEO)	Sale	10,000	37.24	372,430
2015-12-01	Schatzman Randall C (President and CEO)	Option Ex	10,000	.39	3,850
2015-11-30	Dow Stephen M	Sale	88	37.11	3,265
2015-11-02	Latham John A (Chief Scientific Officer)	Sale	4,545	33.48	152,148
2015-11-02	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-11-02	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	33.71	131,457
2015-11-02	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-11-02	Schatzman Randall C (President and CEO)	Sale	10,000	33.51	335,140
2015-11-02	Schatzman Randall C (President and CEO)	Option Ex	10,000	.39	3,850
2015-10-01	Latham John A (Chief Scientific Officer)	Sale	4,545	32.55	147,939
2015-10-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-10-01	Litton Mark James (Chief Business Officer)	Sale	7,500	32.52	243,870
2015-10-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	32.53	126,878
2015-10-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-09-24	Latham John A (Chief Scientific Officer)	Option Ex	31,818	.99	31,499
2015-09-24	Litton Mark James (Chief Business Officer)	Option Ex	12,764	1.26	16,146
2015-09-24	Benedict Larry (Sr. VP Finance)	Option Ex	24,981	2.97	74,193
2015-09-01	Latham John A (Chief Scientific Officer)	Sale	4,545	38.68	175,786
2015-09-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-09-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	38.56	150,399
2015-09-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-08-31	Sevin Rosen Ix Affiliates Fund L.p.	Sale	16,218	38.75	628,463
2015-08-31	Dow Stephen M	Sale	16,218	38.75	628,463
2015-08-12	Sevin Rosen Ix Affiliates Fund L.p.	Sale	97,109	40.03	3,887,370
2015-08-12	Sturiale Nicholas G	Sale	97,109	40.03	3,887,370
2015-08-12	Dow Stephen M	Sale	97,109	40.03	3,887,370
2015-08-11	Sevin Rosen Ix Affiliates Fund L.p.	Sale	115,358	40.40	4,660,809
2015-08-11	Sturiale Nicholas G	Sale	115,358	40.40	4,660,809
2015-08-11	Dow Stephen M	Sale	115,358	40.40	4,660,809
2015-08-03	Latham John A (Chief Scientific Officer)	Sale	4,545	45.62	207,324
2015-08-03	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-08-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	45.64	178,003
2015-08-03	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-07-01	Latham John A (Chief Scientific Officer)	Sale	4,545	51.13	232,381
2015-07-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-07-01	Litton Mark James (Chief Business Officer)	Sale	7,500	51.10	383,220
2015-07-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	51.18	199,617
2015-07-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-06-12	Benedict Larry (Sr. VP Finance)	Sale	25,454	47.46	1,208,097
2015-06-12	Benedict Larry (Sr. VP Finance)	Option Ex	25,454	1.65	41,999
2015-06-04	Latham John A (Chief Scientific Officer)	Sale	25,000	44.18	1,104,475
2015-06-04	Latham John A (Chief Scientific Officer)	Option Ex	25,000	.39	9,625
2015-06-04	Litton Mark James (Chief Business Officer)	Sale	25,000	44.27	1,106,850
2015-06-04	Litton Mark James (Chief Business Officer)	Option Ex	25,000	.39	9,625
2015-06-01	Latham John A (Chief Scientific Officer)	Sale	4,545	41.53	188,758
2015-06-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-06-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	41.53	161,967
2015-06-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-05-26	Schatzman Randall C (President and CEO)	Sale	50,000	38.96	1,948,100
2015-05-26	Schatzman Randall C (President and CEO)	Option Ex	50,000	.39	19,250
2015-05-22	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	7,202	38.47	277,024
2015-05-22	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	7,202	.06	396
2015-05-21	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	54,616	38.92	2,125,490
2015-05-21	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	54,616	.06	3,003
2015-05-21	Dow Stephen M	Sale	20,000	65.69	1,313,839
2015-05-19	Sevin Rosen Ix Affiliates Fund L.p.	Sale	1,136,100	37.02	42,059,558
2015-05-19	Benedict Larry (Sr. VP Finance)	Sale	20,000	38.86	777,200
2015-05-19	Benedict Larry (Sr. VP Finance)	Option Ex	20,000	1.65	33,000
2015-05-18	Siegall Clay B (Director)	Sale	20,000	39.97	799,419
2015-05-14	Siegall Clay B (Director)	Sale	18,181	35.04	637,080
2015-05-14	Siegall Clay B (Director)	Option Ex	18,181	.33	5,999
2015-05-01	Latham John A (Chief Scientific Officer)	Sale	4,545	25.67	116,661
2015-05-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-05-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	25.67	100,128
2015-05-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-04-01	Latham John A (Chief Scientific Officer)	Sale	4,545	27.42	124,610
2015-04-01	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-04-01	Litton Mark James (Chief Business Officer)	Sale	7,500	27.41	205,552
2015-04-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	27.43	106,996
2015-04-01	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-03-30	Latham John A (Chief Scientific Officer)	Sale	14,500	30.20	437,914
2015-03-30	Latham John A (Chief Scientific Officer)	Option Ex	14,500	.39	5,582
2015-03-02	Latham John A (Chief Scientific Officer)	Sale	4,545	26.26	119,342
2015-03-02	Latham John A (Chief Scientific Officer)	Option Ex	4,545	.39	1,749
2015-03-02	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	3,900	26.25	102,355
2015-03-02	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	3,900	.39	1,501
2015-01-27	Latham John A (Chief Scientific Officer)	Sale	7,145	28.73	205,275
2015-01-27	Latham John A (Chief Scientific Officer)	Option Ex	7,145	.39	2,750
2015-01-27	Litton Mark James (Chief Business Officer)	Sale	2,300	28.52	65,602
2015-01-27	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	1,200	28.27	33,921
2015-01-27	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	1,200	.39	462
2015-01-27	Schatzman Randall C (President and CEO)	Sale	63,578	28.71	1,825,197
2015-01-26	Latham John A (Chief Scientific Officer)	Sale	7,900	27.98	221,010
2015-01-26	Latham John A (Chief Scientific Officer)	Option Ex	7,900	.39	3,041
2015-01-26	Litton Mark James (Chief Business Officer)	Sale	5,200	28.02	145,730
2015-01-26	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	2,700	27.89	75,316
2015-01-26	Smith Jeffrey T L (Sr. VP Translational Medicine)	Option Ex	2,700	.39	1,039
2015-01-26	Schatzman Randall C (President and CEO)	Sale	36,422	27.93	1,017,230
2014-11-24	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	9,090	16.91	153,739
2014-11-21	Smith Jeffrey T L (Sr. VP Translational Medicine)	Sale	20,000	15.71	314,120
2014-11-20	Litton Mark James (Chief Business Officer)	Sale	30,000	15.63	469,020
2014-05-13	Bridger Gary (Director)	Buy	250,000	10.00	2,500,000
2014-05-13	Ventures West 8 Limited Partnership (10% Owner)	Buy	250,000	10.00	2,500,000
2014-05-13	Novo A/s (Other)	Buy	550,000	10.00	5,500,000
2014-05-13	Montgomery Alan Bruce (Director)	Buy	3,000	10.00	30,000
2014-05-13	Pakianathan Deepika (Director)	Buy	350,000	10.00	3,500,000
2014-05-13	Bochnowski James J (10% Owner)	Buy	350,000	10.00	3,500,000

Insider trading activities including stock purchases, stock sales, and option exercises of ALDR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Alder Biopharmaceuticals Inc (symbol ALDR, CIK number 1423824) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month